{"id":22537,"date":"2022-11-29T09:29:05","date_gmt":"2022-11-29T08:29:05","guid":{"rendered":"https:\/\/idibell.cat\/?p=22537"},"modified":"2022-11-29T10:08:30","modified_gmt":"2022-11-29T09:08:30","slug":"nous-models-de-ratoli-obren-vies-de-recerca-per-a-tractaments-personalitzats-en-cancer-dendometri","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/11\/nous-models-de-ratoli-obren-vies-de-recerca-per-a-tractaments-personalitzats-en-cancer-dendometri\/","title":{"rendered":"Nous models de ratol\u00ed obren vies de recerca per a tractaments personalitzats en c\u00e0ncer d\u2019endometri"},"content":{"rendered":"

Ara, un equip d\u2019investigadors de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL<\/a>), l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO<\/a>) i l\u2019Hospital Universitari de Bellvitge (HUB<\/a>) ha generat un model de ratol\u00ed capa\u00e7 de mimetitzar fidelment els tumors d\u2019endometri hum\u00e0. Aquest nou model, que es genera a partir d\u2019una bi\u00f2psia del tumor original, pot ser la base per a la recerca de nous tractaments<\/strong>, i m\u00e9s important, permetre estudiar individualment cada tumor per definir el millor tractament per a cada pacient. Els resultats de l\u2019estudi han estat publicats a la revista Advanced Science<\/em><\/a>.<\/p>\n

En els \u00faltims 40 anys no s\u2019ha aconseguit allargar l\u2019esperan\u00e7a de vida de les dones amb c\u00e0ncer d\u2019endometri. Les opcions terap\u00e8utiques per tractar aquest c\u00e0ncer son limitades, quan una pacient deixa de respondre al tractament principal existeixen molt poques alternatives<\/strong> per combatre el c\u00e0ncer.<\/p>\n

El Dr. David Llobet-Navas<\/strong>, investigador principal de l\u2019IDIBELL i un dels tres l\u00edders del projecte, explica: \u201cAquest nou model ens permetr\u00e0 estudiar en temps real quina \u00e9s la millor opci\u00f3 terap\u00e8utica per aquella pacient en concret i avan\u00e7ar-nos a la evoluci\u00f3 de la malaltia, i aix\u00ed ser m\u00e9s efectius i evitar efectes secundaris no desitjats<\/em>.\u201d<\/p>\n

 <\/p>\n

Un model de ratol\u00ed on implantar tumors humans<\/h3>\n

\"\"Per generar el model, els investigadors han implantat en ratolins una bi\u00f2psia del tumor hum\u00e0 en el mateix teixit del ratol\u00ed. En total, en aquest projecte, han estudiat una col\u00b7lecci\u00f3 de 15 ratolins amb 15 tumors humans d\u2019endometri diferents.<\/p>\n

Despr\u00e9s d\u2019implantar els tumors en els ratolins, i deixar que evolucionin durant 100 dies, aproximadament, els investigadors han determinat que els implants mantenen les caracter\u00edstiques moleculars i morfol\u00f2giques dels tumors originals<\/strong>, convertint-los en un gran model per a la recerca.<\/p>\n

\u201cEl c\u00e0ncer no \u00e9s una malaltia homog\u00e8nia, al contrari, cada cas \u00e9s diferent i hi ha molts factors que hi intervenen, no nom\u00e9s gen\u00e8tics sin\u00f3 tamb\u00e9 del entorn on es troba el tumor. Per aix\u00f2 aquest model ens es tan \u00fatil, ja que reprodueix el comportament d\u2019un tumor hum\u00e0 en el seu ambient<\/em>\u201d, afirma el Dr. Alberto Villanueva<\/strong>, tamb\u00e9 l\u00edder del projecte, i cap de grup de recerca de l\u2019IDIBELL i l\u2019Institut Catal\u00e0 d\u2019Oncologia.<\/p>\n

 <\/p>\n

Recerca de nous tractaments pel c\u00e0ncer d\u2019endometri<\/h3>\n

Entre el 15 i el 20% de les pacients amb c\u00e0ncer d\u2019endometri desenvolupen resist\u00e8ncia al tractament, el que suposa un gran problema quan no hi ha alternatives terap\u00e8utiques eficaces. En conseq\u00fc\u00e8ncia, l\u2019esperan\u00e7a de vida d\u2019aquestes dones \u00e9s inferior a un any.<\/p>\n

En aquest estudi del Campus de Bellvitge, gr\u00e0cies al nou model, han comprovat que els tumors que presenten una mutaci\u00f3 concreta en el gen HER2 son sensibles a un f\u00e0rmac anomenat trastuzumab<\/strong>. En estudis previs i assajos cl\u00ednics actualment en marxa ja s\u2019havia<\/span> apuntat a la possible efectivitat d\u2019aquest compost en un percentatge redu\u00eft de pacients amb carcinoma d’endometri. Aquest estudi obre el ventall d’oportunitat terap\u00e8utica a m\u00e9s pacients.<\/p>\n

\u201cHem generat un model que pot impulsar la recerca en c\u00e0ncer d\u2019endometri, en especial la l\u2019exploraci\u00f3 de noves vies terap\u00e8utiques, ja que hem comprovat que podem reproduir perfils gen\u00e8tics en els tumors que desvetllen inesperades vulnerabilitats<\/em>\u201d, declara el Dr. Xavier Matias-Guiu<\/strong>, cap del grup de recerca en c\u00e0ncer ginecol\u00f2gic de l\u2019IDIBELL i Cap del Servei d\u2019Anatomia Patol\u00f2gica el HUB.<\/p>\n

 <\/p>\n

Aquest projecte ha estat finan\u00e7at per La Fundaci\u00f3 La Marat\u00f3, L’Associaci\u00f3 Espanyola Contra el C\u00e0ncer (AECC), l’Instituto Carlos III, European Regional Development Fund i la Genralitat de Catalunya.<\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) <\/em><\/strong>\u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Per generar el nou model s\u2019implanta una bi\u00f2psia fresca del tumor original en el mateix teixit del ratol\u00ed. El que reprodueix perfectament les caracter\u00edstiques morfol\u00f2giques i moleculars originals, i, per tant, permet avan\u00e7ar-se a l\u2019evoluci\u00f3 del tumor per escollir el millor tractament.<\/p>\n","protected":false},"author":8,"featured_media":22538,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,365,447,452,346],"tags":[],"class_list":["post-22537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-ginecologic","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure","category-quimioresistencia-tumoral-i-estromal"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 18:37:20","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22537"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22537\/revisions"}],"predecessor-version":[{"id":22542,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22537\/revisions\/22542"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22538"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}